Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback